Category: Approval/Launch Region: Europe · United Kingdom Company: Astrazeneca Ltd

EMA committee recommends approval of trastuzumab deruxtecan for patients with HER2 positive metastatic breast cancer treated with a prior anti-HER2-based regimen

By, Admin 1 min read
Share
EMA committee recommends approval of trastuzumab deruxtecan for patients with HER2 positive metastatic breast cancer treated with a prior anti-HER2-based regimen
Daiichi Sankyo and AstraZeneca

Found this useful? Share it with your team.

Welcome Back Sign in to Continue

Don't Have an Account? Sign Up!
Forgot Password?

Create your Account!

Don't Have an Account? Sign Up!